Showing results (361-370 of 380) with videos related to
Sort By:
Pageof 38
JMIR Human Factors|September 8, 2025
Personalized Interactive Music Systems for Physical Activity and Exercise: Exploratory Systematic Review and Meta-AnalysisAndrew Danso, Tiia Kekäläinen, Friederike Koehler, et al.Gynecologic Oncology|August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancerDavid M O'Malley, Ana Oaknin, Bradley J Monk, et al.Blood|October 1, 2009
Soluble lymphotoxin is an important effector molecule in GVHD and GVLKate A Markey, Angela C Burman, Tatjana Banovic, et al.Nature Methods|June 29, 2019
Best practices and benchmarks for intact protein analysis for top-down mass spectrometryDaniel P Donnelly, Catherine M Rawlins, Caroline J DeHart, et al.JAMA Network Open|May 15, 2025
Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical HysterectomyChristopher M Tarney, Chunqiao Tian, Leslie M Randall, et al.Gynecologic Oncology|October 27, 2023
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)Leslie M Randall, David M O'Malley, Bradley J Monk, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 20, 2010
Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral malariaFiona H Amante, Ashraful Haque, Amanda C Stanley, et al.British Journal of Anaesthesia|May 28, 2020
Global Tracheostomy Collaborative: data-driven improvements in patient safety through multidisciplinary teamwork, standardisation, education, and patient partnershipMichael J Brenner, Vinciya Pandian, Carly E Milliren, et al.Molecular Cancer Therapeutics|August 28, 2020
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.NPJ Precision Oncology|May 30, 2026
Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancerDoris Kim, Heekyung Chung, Mona Abed, et al.Pageof 38